Vir Biotechnology Inc (VIR)

Total asset turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019
Revenue (ttm)	US$ in thousands	86,180	118,803	490,721	444,237	1,613,740	2,377,077	2,106,136	2,325,891	1,095,407	284,394	182,706	72,626	76,368	75,614	75,089
Total assets	US$ in thousands	1,919,060	2,044,900	2,243,870	2,665,940	2,802,090	2,695,970	2,618,990	2,887,130	1,954,270	1,210,210	1,057,580	1,135,580	918,761	943,259	672,238	477,114	512,071	422,642
Total asset turnover		0.04	0.06	0.22	0.17	0.58	0.88	0.80	0.81	0.56	0.23	0.17	0.06	0.08	0.08	0.11

December 31, 2023 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $86,180K ÷ $1,919,060K
= 0.04

Total asset turnover is a financial ratio that measures a company's ability to generate revenue from its assets. A higher total asset turnover indicates that the company is more efficient in utilizing its assets to generate revenue.

Looking at the data provided for Vir Biotechnology Inc, we observe fluctuations in the total asset turnover ratio over the past eight quarters. In the most recent quarter, Q4 2023, the total asset turnover ratio is 0.04, which is relatively low compared to the preceding quarters. This suggests that the company is generating less revenue relative to its total assets in this period.

In contrast, the total asset turnover ratio was highest in Q4 2022 at 0.58, indicating that the company was more efficient in generating revenue from its assets during that period. Subsequently, the ratio decreased over the following quarters but remained relatively stable around 0.80 in the middle of 2022 before declining again.

The fluctuation in total asset turnover ratios could indicate changes in the company's operational efficiency, asset management, or revenue generation strategies over the analyzed periods. Further analysis and comparison with industry benchmarks or competitors' ratios would provide more insight into Vir Biotechnology Inc's performance and efficiency in utilizing its assets to generate revenue.